Supriya Lifescience Ltd. News and Updates

Name: Latest research reports of Supriya Lifescience Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Supriya Lifescience Ltd.
Rating: 5
Author: KRChoksey

Keep track of all breaking news on Supriya Lifescience Ltd. from all sources in a single place.

Supriya Lifescience Ltd.

28 Jan 2025

629.00

-1.43%

Increased focus on niche therapies and regulated markets aid growth

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

SUPRIYA revenue beat our estimates significantly due to strong growth in Analgesic segment and regulated markets. EBITDA and Adj. PAT exceeded our estimates significantly due to better-than-expected gross profit, and lower than expected operating expenses.

Supriya Lifescience .. has an average target of 740.00 from 1 broker.

Supriya Lifescience Ltd.

27 Jan 2025

629.00

-1.43%

Supriya Lifescience plummets 6% after Q3FY25 results; details here

Business Standard

Supriya Lifescience share slipped 5.65 per cent at Rs 661.20 a piece on the BSE in Monday's intraday trade despite the pharma company reporting strong quarterly earnings for the financial year 2024-25

Supriya Lifescience .. has an average target of 740.00 from 1 broker.

Supriya Lifescience Ltd.

27 Jan 2025

629.00

-1.43%

to see Rapid results content

Supriya Lifescience Ltd.

27 Jan 2025

629.00

-1.43%

Supriya Lifescience Results Earnings Call for Q3FY25

Conference Call with Supriya Lifescience Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.

Supriya Lifescience Ltd.

31 Dec 2024

629.00

-1.43%

Supriya Lifescience share price soars 7% in weak market today; here's why

Business Standard

Supriya Lifescience Chairman and Whole-Time Director Satish Wagh said he was confident of achieving 22 per cent year-on-year revenue growth in the current financial year (FY25)

Supriya Lifescience Ltd. is trading below all available SMAs

Supriya Lifescience Ltd.

18 Dec 2024

629.00

-1.43%

Supriya Lifesciences jumps 6% after co expands capacity at API unit

Business Standard

Supriya Lifesciences share price surged after the company inaugurated a new active pharmaceutical ingredients (APIs) production block, Module E, at the Lote Parshuram site in Maharashtra

Supriya Lifescience Ltd. is trading below all available SMAs

Supriya Lifescience Ltd.

29 Oct 2024

629.00

-1.43%

to see Rapid results content

Supriya Lifescience Ltd.

29 Oct 2024

629.00

-1.43%

Strong operational performance continue with multiple growth levers

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

Supriya Lifescience revenue slightly missed (-1.2%) our estimate. However, EBITDA and PAT beat our estimates significantly due to lower-than-expected operating expenses, better product mix and better geographical mix.

Number of FII/FPI investors increased from 85 to 98 in Mar 2025 qtr.

Supriya Lifescience Ltd.

28 Oct 2024

629.00

-1.43%

Supriya Lifescience Results Earnings Call for Q2FY25

Conference Call with Supriya Lifescience Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.

Supriya Lifescience Ltd.

20 Sep 2024

629.00

-1.43%

Supriya Life Challenges China Dominance On Drug Ingredients For Topline Boost

NDTV Profit

Supriya Lifesciences is going to 'crack some products' manufactured exclusively by China, as they will lead to better results and Ebitda margins, said Chairman Satish Wagh.